Clinical Trial Update: Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cabozantinib in combination with pembrolizumab for metastatic gastric cancer and gastroesophageal cancer; results have been posted and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Cancer

Drugs mentioned

• Cabometyx (cabozantinib)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: University of California, Irvine | Conditions: Gastric Adenocarcinoma, GastroEsophageal Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-08-11